Prelude Capital Management’s Amedisys AMED Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-90,361
| Closed | -$8.89M | – | 1134 |
|
|
2025
Q2 | $8.89M | Buy |
90,361
+36,974
| +69% | +$3.5M | 0.86% | 11 |
|
|
2025
Q1 | $4.95M | Buy |
53,387
+31,153
| +140% | +$2.87M | 0.38% | 50 |
|
|
2024
Q4 | $2.02M | Sell |
22,234
-56,665
| -72% | -$5.2M | 0.13% | 183 |
|
|
2024
Q3 | $7.61M | Sell |
78,899
-6,831
| -8% | -$667K | 0.46% | 22 |
|
|
2024
Q2 | $7.87M | Buy |
85,730
+25,387
| +42% | +$2.36M | 0.55% | 20 |
|
|
2024
Q1 | $5.56M | Buy |
60,343
+16,999
| +39% | +$1.59M | 0.29% | 52 |
|
|
2023
Q4 | $4.12M | Sell |
43,344
-2,976
| -6% | -$278K | 0.27% | 69 |
|
|
2023
Q3 | $4.33M | Buy |
46,320
+32,411
| +233% | +$2.99M | 0.28% | 72 |
|
|
2023
Q2 | $1.27M | Buy |
+13,909
| New | +$1.14M | 0.08% | 272 |
|
|
2022
Q4 | – | Sell |
-3,640
| Closed | -$352K | – | 1314 |
|
|
2022
Q3 | $352K | Buy |
3,640
+428
| +13% | +$51K | 0.01% | 802 |
|
|
2022
Q2 | $338K | Buy |
+3,212
| New | +$410K | 0.01% | 1000 |
|
|
2022
Q1 | – | Sell |
-3,965
| Closed | -$592K | – | 1784 |
|
|
2021
Q4 | $642K | Buy |
+3,965
| New | +$637K | 0.02% | 864 |
|
|
2020
Q1 | – | Sell |
-45
| Closed | -$8K | – | 1402 |
|
|
2019
Q4 | $8K | Buy |
+45
| New | +$6.69K | ﹤0.01% | 1726 |
|
|
2019
Q3 | – | Sell |
-300
| Closed | -$36K | – | 1687 |
|
|
2019
Q2 | $36K | Sell |
300
-397
| -57% | -$47.1K | ﹤0.01% | 1191 |
|
|
2019
Q1 | $86K | Sell |
697
-99
| -12% | -$12.4K | ﹤0.01% | 973 |
|
|
2018
Q4 | $93K | Buy |
796
+446
| +127% | +$52.6K | 0.01% | 952 |
|
|
2018
Q3 | $44K | Buy |
350
+250
| +250% | +$27.6K | ﹤0.01% | 1157 |
|
|
2018
Q2 | $9K | Buy |
+100
| New | +$7.34K | ﹤0.01% | 1495 |
|
|
2018
Q1 | – | Sell |
-1,700
| Closed | -$90K | – | 1476 |
|
|
2017
Q4 | $90K | Hold |
1,700
| – | – | 0.01% | 807 |
|
|
2017
Q3 | $95K | Buy |
+1,700
| New | +$89.9K | 0.01% | 890 |
|
|
2017
Q2 | – | Sell |
-600
| Closed | -$31K | – | 1581 |
|
|
2017
Q1 | $31K | Buy |
+600
| New | +$28.6K | ﹤0.01% | 1174 |
|
|
2016
Q1 | – | Sell |
-5,673
| Closed | -$223K | – | 1239 |
|
|
2015
Q4 | $223K | Sell |
5,673
-81
| -1% | -$3.24K | 0.03% | 513 |
|
|
2015
Q3 | $218K | Buy |
+5,754
| New | +$243K | 0.03% | 548 |
|
|
2015
Q2 | – | Sell |
-1,500
| Closed | -$40K | – | 1668 |
|
|
2015
Q1 | $40K | Hold |
1,500
| – | – | 0.01% | 1427 |
|
|
2014
Q4 | $44K | Sell |
1,500
-2,400
| -62% | -$59.3K | 0.01% | 1293 |
|
|
2014
Q3 | $79K | Buy |
3,900
+1,300
| +50% | +$25.1K | 0.01% | 1198 |
|
|
2014
Q2 | $44K | Buy |
+2,600
| New | +$36.8K | 0.01% | 1407 |
|
|
2014
Q1 | – | Sell |
-2,050
| Closed | -$31.5K | – | 1838 |
|
|
2013
Q4 | $30K | Sell |
2,050
-200
| -9% | -$3.22K | 0.01% | 1274 |
|
|
2013
Q3 | $39K | Buy |
+2,250
| New | +$33.4K | 0.01% | 970 |
|
Other funds holding AMED
IA
MCI
HNB
Prelude Capital Management's AMED Position: Q3 2025 in Review
Prelude Capital Management sold out of Amedisys (AMED) in Q3 2025, closing a stake of 90,361 shares — an estimated $8.89M sold.
Prelude Capital Management first reported a position in AMED in Q3 2013 and held it in 29 quarters. The position peaked at $8.89M in Q2 2025. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.
- Prelude Capital Management reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
- Prelude Capital Management sold 90,361 Amedisys shares in Q3 2025, an estimated $8.89M.
- Prelude Capital Management first reported a position in Amedisys in Q3 2013 and held it in 29 quarters.
- Prelude Capital Management's Amedisys position peaked at $8.89M in Q2 2025.
- 4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.
Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.